scholarly journals Patient-reported health outcomes in patients with non-melanoma skin cancer and actinic keratosis: results from a large-scale observational study analysing effects of diagnoses and disease progression

2018 ◽  
Vol 32 (7) ◽  
pp. 1138-1146 ◽  
Author(s):  
W.G. Philipp-Dormston ◽  
K. Müller ◽  
B. Novak ◽  
K. Strömer ◽  
C. Termeer ◽  
...  
Keyword(s):  
Skin Cancer ◽  
Observational Study ◽  
Health Outcomes ◽  
Disease Progression ◽  
Actinic Keratosis ◽  
Large Scale ◽  
Non Melanoma Skin Cancer ◽  
Patient Reported ◽  
Reported Health ◽  
Melanoma Skin

scholarly journals Management of Acute Radiodermatitis in Non-Melanoma Skin Cancer Patients Using Electrospun Nanofibrous Patches Loaded with Pinus halepensis Bark Extract

Cancers ◽  
2021 ◽  
Vol 13 (11) ◽  
pp. 2596
Author(s):  
Aikaterini Kyritsi ◽  
Stefanos Kikionis ◽  
Anna Tagka ◽  
Nikolaos Koliarakis ◽  
Antonia Evangelatou ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Skin Cancer ◽  
Cancer Patients ◽  
Pinus Halepensis ◽  
Radiation Therapy Oncology Group ◽  
Bark Extract ◽  
Skin Reactions ◽  
Non Melanoma Skin Cancer ◽  
Patient Reported ◽  
Melanoma Skin

Acute radiodermatitis is the most common side effect in non-melanoma skin cancer patients undergoing radiotherapy. Nonetheless, despite the ongoing progress of clinical trials, no effective regimen has been found yet. In this study, a non-woven patch, comprised of electrospun polymeric micro/nanofibers loaded with an aqueous extract of Pinus halepensis bark (PHBE), was fabricated and clinically tested for its efficacy to prevent radiodermatitis. The bioactivity of the PHBE patch was evaluated in comparison with a medical cream indicated for acute radiodermatitis. Twelve volunteer patients were selected and randomly assigned to two groups, applying either the PHBE patch or the reference cream daily. Evaluation of radiation-induced skin reactions was performed during the radiotherapy period and 1 month afterwards according to the Radiation Therapy Oncology Group (RTOG) grading scale, photo-documentation, patient-reported outcomes (Visual Analog Scale, questionnaire), biophysical measurements (hydration, transepidermal water loss, erythema, melanin), and image analysis. In contrast with the reference product, the PHBE patch showed significant anti-inflammatory activity and restored most skin parameters to normal levels 1 month after completion of radiation therapy. No adverse event was reported, indicating that the application of the PHBE patch can be considered as a safe medical device for prophylactic radiodermatitis treatment.

Synthesis, biological evaluation and SAR of 3-benzoates of ingenol for treatment of actinic keratosis and non-melanoma skin cancer

2014 ◽  
Vol 24 (1) ◽  
pp. 54-60 ◽  
Author(s):  
Gunnar Grue-Sørensen ◽  
Xifu Liang ◽  
Kristoffer Månsson ◽  
Per Vedsø ◽  
Morten Dahl Sørensen ◽  
...  
Keyword(s):  
Skin Cancer ◽  
Actinic Keratosis ◽  
Biological Evaluation ◽  
Non Melanoma Skin Cancer ◽  
Melanoma Skin

Syntheses, biological evaluation and SAR of ingenol mebutate analogues for treatment of actinic keratosis and non-melanoma skin cancer

2013 ◽  
Vol 23 (20) ◽  
pp. 5624-5629 ◽  
Author(s):  
Xifu Liang ◽  
Gunnar Grue-Sørensen ◽  
Kristoffer Månsson ◽  
Per Vedsø ◽  
Anke Soor ◽  
...  
Keyword(s):  
Skin Cancer ◽  
Actinic Keratosis ◽  
Biological Evaluation ◽  
Ingenol Mebutate ◽  
Non Melanoma Skin Cancer ◽  
Melanoma Skin

scholarly journals Cost for the treatment of actinic keratosis on the rise in Australia

F1000Research ◽  
2014 ◽  
Vol 3 ◽  
pp. 184 ◽  
Author(s):  
Eshini Perera ◽  
Sean McGuigan ◽  
Rodney Sinclair
Keyword(s):  
Retrospective Study ◽  
Skin Cancer ◽  
Actinic Keratosis ◽  
Published Data ◽  
Non Melanoma Skin Cancer ◽  
Melanoma Skin

Objectives: To report the burden and cost of actinic keratosis (AK) treatment in Australia and to forecast the number of AK treatments and the associated costs to 2020.Design and setting: A retrospective study of data obtained from medicare Australia for AK treated by cryotherapy between 1 January 1994 and 31 December 2012, by year and by state or territory.Results: The total number of AK cryotherapy treatments increased from 247,515 in 1994 to 643,622 in 2012, and we estimate that the number of treatments will increase to 831,952 (95% CI 676,919 to 986,987) by 2020. The total Medicare Benefits Schedule (MBS) benefits paid out for AK in 2012 was $19.6 million and we forecast that this will increase to $24.7 million by 2020 (without inflation).Conclusion: The number of AK cryotherapy treatments increased by 160% between 1994 and 2012. we forecast that the number of treatments will increase by 30% between 2012 and 2020. The rates of non-melanoma skin cancer (NMSC) and AK appear to be increasing at the same rate. During the period 2010 to 2015 AK is anticipated to increase by 17.8% which follows a similar trend to published data that forecasts an increase in NMSC treatments of 22.3%.

Sign in / Sign up

Export Citation Format

Share Document